Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Study of WZTL-002 CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Primary Mediastinal Large B-cell Lymphoma (PMBCL)
Transformed Non-Hodgkin Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Biological: WZTL-002 CAR T-cells

First Posted Date: 2024-07-03

Last Posted Date: 2024-07-22

Lead Sponsor: Malaghan Institute of Medical Research

Target Recruit Count: 60

Registration Number: NCT06486051

Locations: 🇳🇿
Wellington Hospital, Newtown, Wellington, New Zealand

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Phase 1

Recruiting

Conditions: Acute Lymphocytic Leukemia

Interventions: Biological: TCR reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T cell
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-07-01

Last Posted Date: 2024-12-02

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 30

Registration Number: NCT06481735

Locations: 🇨🇳
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China

A Phase 1/2 Trial of ADI-270 in CcRCC

Phase 1

Recruiting

Conditions: Clear Cell Renal Cell Carcinoma

Interventions: Drug: ADI-270
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-06-28

Last Posted Date: 2024-11-22

Lead Sponsor: Adicet Therapeutics

Target Recruit Count: 60

Registration Number: NCT06480565

Locations: 🇺🇸
Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee, United States

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Lymphoblastic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Biological: CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
Biological: Cetuximab
Procedure: Computed Tomography
Drug: Cyclophosphamide
Procedure: Echocardiography
Drug: Fludarabine
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Procedure: Multigated Acquisition Scan
Procedure: Positron Emission Tomography

First Posted Date: 2024-06-07

Last Posted Date: 2024-12-31

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 24

Registration Number: NCT06447987

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

Phase 1

Recruiting

Conditions: Systemic Sclerosis
Autoimmune Disorders

Interventions: Drug: Tafasitamab
Drug: Fludarabine phosphate
Drug: Cyclophosphamide

First Posted Date: 2024-05-30

Last Posted Date: 2024-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 47

Registration Number: NCT06434363

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Phase 1

Recruiting

Conditions: Locally Advanced Solid Tumor
Metastatic Solid Tumor

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: ACE2016
Drug: Pembrolizumab

First Posted Date: 2024-05-16

Last Posted Date: 2024-12-05

Lead Sponsor: Acepodia Biotech, Inc.

Target Recruit Count: 30

Registration Number: NCT06415487

Locations: 🇺🇸
University of California San Diego, San Diego, California, United States
🇺🇸
Texas Oncology, Dallas, Texas, United States
🇨🇳
Taipei Veterans General Hospital, Taipei City, Beitou District, Taiwan

and more 6 locations

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Phase 2

Recruiting

Conditions: Acquired Amegakaryocytic Thrombocytopenia
Acquired Pure Red Cell Aplasia
Severe Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria

Interventions: Drug: Rituximab
Drug: Rabbit ATG
Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total Body Irradiation
Biological: Cell Infusion
Drug: Post-Transplant G-CSF
Drug: Tacrolimus
Drug: Mycophenolate Mofetil

First Posted Date: 2024-05-14

Last Posted Date: 2024-06-10

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 60

Registration Number: NCT06412497

Locations: 🇺🇸
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Anitocabtagene Autoleucel
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Fludarabine
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib

First Posted Date: 2024-05-14

Last Posted Date: 2024-12-19

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 450

Registration Number: NCT06413498

Locations: 🇺🇸
UCLA Department of Medicine-Hematology/Oncology, Santa Monica, California, United States
🇺🇸
Baptist Cancer Center, Memphis, Tennessee, United States
🇦🇺
Epworth HealthCare, Richmond, Victoria, Australia

and more 4 locations